Study of Tamoxifen and Raloxifene (STAR)
Semantic Scholar uses AI to extract papers important to this topic.
The Study of Tamoxifen and Raloxifene (STAR) demonstrated that raloxifene was as effective as tamoxifen in reducing the… Expand The selective estrogen-receptor modulator (SERM) tamoxifen became the first U.S. Food and Drug Administration (FDA)–approved… Expand In the Study of Tamoxifen and Raloxifene (STAR) trial, postmenopausal women at increased risk of breast cancer received either… Expand PURPOSE
To compare the effects of two selective estrogen receptor modulators, tamoxifen and raloxifene, on global and domain… Expand CONTEXT
Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast… Expand ContextTamoxifen has been approved for breast cancer risk reduction in high-risk women, but how raloxifene compares with… Expand CONTEXT
Tamoxifen has been approved for breast cancer risk reduction in high-risk women, but how raloxifene compares with… Expand The selective estrogen receptor modulator (SERM) tamoxifen has long been used to treat both early and advanced breast cancer… Expand I. Introduction II. Lacassagne’s Prevention Principle: A Target and an Estrogen Antagonist III. Tamoxifen as an Antitumor Agent A… Expand